US 12,442,827 B2
Detection and treatment of conditions related to luteinizing hormone/follicle-stimulating hormone (LH/FSH) levels
Dimitrios Karamichos, Carrollton, TX (US)
Assigned to UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH, Fort Worth, TX (US); and THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA, Norman, OK (US)
Appl. No. 17/775,040
Filed by UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH, Fort Worth, TX (US); and THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA, Norman, OK (US)
PCT Filed Nov. 5, 2020, PCT No. PCT/US2020/059128
§ 371(c)(1), (2) Date May 6, 2022,
PCT Pub. No. WO2021/092187, PCT Pub. Date May 14, 2021.
Claims priority of provisional application 62/932,099, filed on Nov. 7, 2019.
Prior Publication US 2022/0390474 A1, Dec. 8, 2022
Int. Cl. G01N 33/76 (2006.01)
CPC G01N 33/76 (2013.01) [G01N 2333/59 (2013.01); G01N 2800/04 (2013.01)] 18 Claims
 
1. A method for treating a disease or condition of the eye related to a ratio of luteinizing hormone to follicle-stimulating hormone (LH/FSH ratio) comprising:
obtaining or having obtained a biological sample from a subject;
determining the LH/FSH ratio in the biological sample, wherein a decrease in the LH/FSH ratio when compared to an age-matched subject that does not have a disease or condition of the eye related to an LH/FSH ratio is indicative of a current or future disease or condition of the eye related to an LH/FSH ratio in the subject;
and administering to the subject with a decrease in the LH/FSH ratio an effective amount of gonadotropes, pituitary hormones, Gonadotropin-releasing hormones, LH, FSH, dehydroepiandrosterone sulfate (DHEA-S), Estrone, Estriol, or sex hormones, with a Prolactin-Inducible Protein (PIP) or a Gonadotropin-releasing hormone (GNRH) in an amount sufficient to increase the LH/FSH ratio.